Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why

With an annual dividend yield of 3.75%, Novo Nordisk A/S (NYSE:NVO) is included among the 12 Best NYSE Stocks to Buy for Dividends.Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why

Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered in Denmark.

On June 19, Nordea upgraded Novo Nordisk A/S (NYSE:NVO) from 'Hold' to 'Buy' and assigned the stock a price target of DKK 350, implying an upside of 10% from the current levels.

The analyst firm expects the near-term news flow to be favorable for the pharma company. Nordea also believes that the sales of Novo's Wegovy pill could exceed market expectations, further supporting its bullish sentiment.

Notably, on June 11, Novo Nordisk's Wegovy pill became the first daily GLP-1 weight-loss pill approved in the UK. This paves the way for the Danish pharma giant to launch the drug in the second market outside the US this year, after the UAE regulator, Emirates Drug Establishment, already approved it earlier this month.

Novo has previously revealed plans to launch the product in select markets in the second half of 2026.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 12 Best NASDAQ Stocks to Buy for Dividends and 12 Best S&P 500 Stocks to Buy for Dividends

Disclosure: None. Follow Insider Monkey on Google News.

View Comments